Sergei Kusmartsev

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2795937/publications.pdf

Version: 2024-02-01

59	7,378	185998 28	243296 44
papers	citations	h-index	g-index

62	62	62	9667
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of ROS Using Oxidized DCFDA and Flow-Cytometry. Methods in Molecular Biology, 2010, 594, 57-72.	0.4	916
2	Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species. Journal of Immunology, 2004, 172, 989-999.	0.4	742
3	Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells. Journal of Immunology, 2009, 182, 5693-5701.	0.4	655
4	Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer. Journal of Immunology, 2004, 172, 464-474.	0.4	418
5	STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion. Journal of Immunology, 2005, 174, 4880-4891.	0.4	390
6	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1117-1122.	3.3	378
7	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Research, 2003, 63, 4441-9.	0.4	350
8	Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation. Journal of Immunology, 2000, 165, 779-785.	0.4	332
9	Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer. Cancer Immunology, Immunotherapy, 2006, 55, 237-245.	2.0	323
10	Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells. Journal of Immunology, 2005, 175, 4583-4592.	0.4	297
11	Immature myeloid cells and cancer-associated immune suppression. Cancer Immunology, Immunotherapy, 2002, 51, 293-298.	2.0	289
12	Reversal of Myeloid Cellâ€“Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2008, 14, 8270-8278.	3.2	268
13	Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. Journal of Leukocyte Biology, 2003, 74, 186-196.	1.5	242
14	Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma. Journal of Immunology, 2008, 181, 346-353.	0.4	236
15	Tumor-Associated Macrophages Mediate Immunosuppression in the Renal Cancer Microenvironment by Activating the 15-Lipoxygenase-2 Pathway. Cancer Research, 2011, 71, 6400-6409.	0.4	190
16	Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer and Metastasis Reviews, 2006, 25, 323-331.	2.7	170
17	Circulating and tumorâ€infiltrating myeloid cell subsets in patients with bladder cancer. International Journal of Cancer, 2012, 130, 1109-1119.	2.3	166
18	Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. Journal of Leukocyte Biology, 2010, 88, 839-848.	1.5	135

#	Article	IF	Citations
19	Mechanisms of immune evasion in bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 3-14.	2.0	127
20	Effects of CXCR4 antagonist CTCEâ€9908 on prostate tumor growth. Prostate, 2009, 69, 1460-1469.	1.2	96
21	Reversal of Tumor-Mediated Immunosuppression. Clinical Cancer Research, 2007, 13, 727s-732s.	3.2	84
22	Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clinical Cancer Research, 2003, 9, 285-94.	3.2	83
23	Calcium Oxalate Stone Fragment and Crystal Phagocytosis by Human Macrophages. Journal of Urology, 2016, 195, 1143-1151.	0.2	72
24	Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer. Journal of Immunology, 2009, 182, 7548-7557.	0.4	68
25	Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2â€²-deoxycytidine. Cancer Immunology, Immunotherapy, 2010, 59, 697-706.	2.0	57
26	Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas. Clinical Cancer Research, 2013, 19, 1670-1680.	3.2	57
27	Calcium Oxalate Differentiates Human Monocytes Into Inflammatory M1 Macrophages. Frontiers in Immunology, 2018, 9, 1863.	2.2	51
28	Aberrant PGE2 metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. International Immunopharmacology, 2011, 11, 848-855.	1.7	39
29	Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nature Reviews Urology, 2009, 6, 540-549.	1.9	30
30	Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression. Molecular Cancer Therapeutics, 2009, 8, 3130-3139.	1.9	27
31	Hyal2 Expression in Tumor-Associated Myeloid Cells Mediates Cancer-Related Inflammation in Bladder Cancer. Cancer Research, 2021, 81, 648-657.	0.4	24
32	Bclâ€2 mediated modulation of vascularization in prostate cancer xenografts. Prostate, 2009, 69, 459-470.	1.2	14
33	Enhanced 15-lipoxygenase activity and elevated eicosanoid production in kidney tumor microenvironment contribute to the inflammation and immune suppression. OncoImmunology, 2012, 1, 249-251.	2.1	9
34	Detection of PD-L1â€“Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes. Journal of Immunology, 2022, 208, 2829-2836.	0.4	9
35	Sialoadhesin expression by bone marrow macrophages derived from Ehrlich-tumor-bearing mice. Cancer Immunology, Immunotherapy, 1999, 48, 493-498.	2.0	6
36	Acute Kidney Injuryâ€“Induced Systemic Inflammation and Risk of Kidney Cancer Formation. Cancer Research, 2021, 81, 2584-2585.	0.4	6

#	Article	IF	Citations
37	Structural and functional organization of bone marrow of AKR/J mice during aging. Bulletin of Experimental Biology and Medicine, 1998, 125, 233-235.	0.3	4
38	Effect of individual and combination treatment with cytokines on expression of sialoadhesin by bone marrow macrophages. Bulletin of Experimental Biology and Medicine, 2003, 136, 139-141.	0.3	4
39	High Levels of PD-L1+ and Hyal2+ Myeloid-derived Suppressor Cells in Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2022, 9, 1-6.	0.2	4
40	Decrease of antitumor and suppressor activities of nonadherent bone marrow cells by culturing in medium conditioned with ehrlich adenocarcinoma cells. Bulletin of Experimental Biology and Medicine, 1994, 117, 513-516.	0.3	2
41	Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells. Journal of Immunotherapy, 2005, 28, 648.	1.2	2
42	Editorial: Roles of Tumor-Recruited Myeloid Cells in Immune Evasion in Cancer. Frontiers in Immunology, 2021, 12, 749605.	2.2	2
43	Adaptive capacity of granulocytic bone marrow stem cells in preleukemic AKR mice. Bulletin of Experimental Biology and Medicine, 1999, 127, 137-139.	0.3	1
44	BCL-2 MODULATES ANGIOGENESIS AND LYMPHANGIOGENESIS IN PC-3 XENOGRAFTS. Journal of Urology, 2008, 179, 389-389.	0.2	1
45	Polymorphonuclear Neutrophils and Cancer: Ambivalent Role in Host Defense Against Tumor. , 2005, , 275-299.		1
46	Suppressor activity of nonadhesive bone marrow cells is determined by the cells bearing erythroblast antigen. Bulletin of Experimental Biology and Medicine, 1993, 115, 735-738.	0.3	0
47	Differential induction of natural suppressor activity of bone marrow cellsin vitro by different types of tumors. Bulletin of Experimental Biology and Medicine, 1995, 120, 829-831.	0.3	0
48	Expression of bone marrow macrophage receptors in cytostatic-induced myelodepression. Bulletin of Experimental Biology and Medicine, 1998, 126, 662-664.	0.3	0
49	Suppressive activity of bone marrow cells from patients with stomach cancer. Effect of prostaglandins, transforming growth factor-Î², and nitric oxide. Bulletin of Experimental Biology and Medicine, 1998, 125, 190-193.	0.3	0
50	Mechanisms of preleukemic hypoplasia of the bone marrow erythroid stem in AKR/JY mice. Bulletin of Experimental Biology and Medicine, 1999, 127, 575-576.	0.3	0
51	Suppressive and antitumor activities of bone marrow cells and splenocytes of AKR mice during aging. Bulletin of Experimental Biology and Medicine, 1999, 127, 410-412.	0.3	0
52	Functional capacities of committed hemopoietic progenitor cells of the bone marrow in AKR/JY mice during the preleukemia period. Bulletin of Experimental Biology and Medicine, 1999, 128, 1162-1164.	0.3	0
53	Role of interferon-Î³ in regulation of antiproliferative activity of bone marrow nonadherent cells. Bulletin of Experimental Biology and Medicine, 1999, 128, 1248-1250.	0.3	0
54	BCL-2 MEDIATED MODULATION OF VASCULARIZATION IN PROSTATE CANCER XENOGRAFTS. Journal of Urology, 2009, 181, 475-476.	0.2	0

#	Article	IF	Citations
55	MP25-12 HUMAN MACROPHAGES FACILITATE KIDNEY STONE CLEARANCES. Journal of Urology, 2014, 191, .	0.2	0
56	MP33-09 HUMAN MONOCYTE-DERIVED MACROPHAGES ARE ABLE TO DESTROY KIDNEY STONES. Journal of Urology, 2015, 193, .	0.2	0
57	MP58-09 HYDROXYAPATITE INDUCES CALCIUM OXALATE TOLERANCE IN PRIMARY HUMAN MONOCYTES. Journal of Urology, 2016, 195, .	0.2	0
58	Abstract B13: Prostate cancer immunotherapy development using tumor-specific CAR design. , 2015, , .		0
59	Development of human NKG2D-CD3Îµ chimeric antigen receptor (CAR) for T-cell-mediated cancer immunotherapy.. Journal of Clinical Oncology, 2017, 35, 150-150.	0.8	0